Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylation: a second hit in the two-hit hypothesis.

J P Geisler1, J A Rathe, K J Manahan

  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

European Journal of Gynaecological Oncology
|October 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer.

European journal of gynaecological oncology·2016
Same author

Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.

European journal of gynaecological oncology·2016
Same author

Cyclin E is overexpressed by clear cell carcinomas of the endometrium and is a prognostic indicator of survival.

European journal of gynaecological oncology·2015
Same author

Robotically-assisted laparoscopic radical parametrectomy and radical vaginectomy.

European journal of gynaecological oncology·2012
Same author

Total colectomy in primary ovarian cytoreduction.

European journal of gynaecological oncology·2011
Same author

Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.

European journal of gynaecological oncology·2008

Methylation of a BRCA1 allele can act as a second hit in patients with a missense mutation on the other allele. This finding is crucial for understanding BRCA1-associated cancer risks.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • BRCA1 gene mutations are linked to hereditary breast and ovarian cancer syndromes.
  • Tumor suppressor genes like BRCA1 typically require two inactivation events (two-hit hypothesis) for cancer development.
  • Understanding the mechanisms of BRCA1 inactivation is critical for risk assessment and therapeutic strategies.

Observation:

  • A patient presented with a missense mutation in one BRCA1 allele.
  • The other BRCA1 allele in the patient was found to be methylated.
  • The patient's genetic locus was diploid, indicating no large-scale deletions or duplications.

Findings:

  • Epigenetic silencing via methylation of one BRCA1 allele can function as the second hit.
  • This mechanism complements the traditional two-hit model involving biallelic mutations.

Related Experiment Videos

  • Methylation serves as an alternative pathway to BRCA1 inactivation in tumorigenesis.

    • Implications:

    • Highlights the role of epigenetic modifications in cancer predisposition.
    • Suggests that methylation analysis may be important in the genetic counseling of patients with BRCA1-related cancer risk.
    • Informs the development of targeted therapies aimed at reversing or overcoming BRCA1 silencing.